Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2010

01.05.2010 | Epidemiology

Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population

verfasst von: Maria A. Loizidou, Marios A. Cariolou, Susan L. Neuhausen, Robert F. Newbold, Evy Bashiardes, Yiola Marcou, Thalia Michael, Maria Daniel, Eleni Kakouri, Panayiotis Papadopoulos, Simon Malas, Andreas Hadjisavvas, Kyriacos Kyriacou

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Inability to correctly repair DNA damage is known to play a role in the development of breast cancer. Single nucleotide polymorphisms (SNPs) of DNA repair genes have been identified, which modify the DNA repair capacity, which in turn may affect the risk of developing breast cancer. To assess whether alterations in DNA repair genes contribute to breast cancer, we genotyped 62 SNPs in 29 genes in 1,109 Cypriot women with breast cancer and 1,177 age-matched healthy controls. Five SNPs were associated with breast cancer. SNPs rs13312840 and rs769416 in the NBS1 gene were associated with a decrease in breast cancer risk (OR TT vs. TC/CC = 0.58; 95% CI, 0.37–0.92; P = 0.019 and OR GG vs. GT/TT = 0.23, 95% CI 0.06–0.85, P = 0.017, respectively). The variant allele of MRE11A rs556477 was also associated with a reduced risk of developing the disease (OR AA vs. AG/GG = 0.76; 95% CI, 0.64–0.91; P = 0.0022). MUS81 rs545500 and PBOV1 rs6927706 SNPs were associated with an increased risk of developing breast cancer (OR GG vs. GC/CC = 1.21, 95% CI, 1.02–1.45; P = 0.031; OR AA vs. AG/GG = 1.53, 95% CI, 1.07–2.18; P = 0.019, respectively). Finally, haplotype-based tests identified significant associations between specific haplotypes in MRE11A and NBS1 genes and breast cancer risk. Further large-scale studies are needed to confirm these results.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed
2.
Zurück zum Zitat Bau DT, Mau YC, Ding SL et al (2007) DNA double-strand break repair capacity and risk of breast cancer. Carcinogenesis 28(8):1726–1730CrossRefPubMed Bau DT, Mau YC, Ding SL et al (2007) DNA double-strand break repair capacity and risk of breast cancer. Carcinogenesis 28(8):1726–1730CrossRefPubMed
3.
Zurück zum Zitat Kennedy DO, Agrawal M, Shen J et al (2005) DNA repair capacity of lymphoblastoid cell lines from sisters discordant for breast cancer. J Natl Cancer Inst 97(2):127–132PubMedCrossRef Kennedy DO, Agrawal M, Shen J et al (2005) DNA repair capacity of lymphoblastoid cell lines from sisters discordant for breast cancer. J Natl Cancer Inst 97(2):127–132PubMedCrossRef
4.
Zurück zum Zitat Machella N, Terry MB, Zipprich J et al (2008) Double-strand breaks repair in lymphoblastoid cell lines from sisters discordant for breast cancer from the New York site of the BCFR. Carcinogenesis 29(7):1367–1372CrossRefPubMed Machella N, Terry MB, Zipprich J et al (2008) Double-strand breaks repair in lymphoblastoid cell lines from sisters discordant for breast cancer from the New York site of the BCFR. Carcinogenesis 29(7):1367–1372CrossRefPubMed
5.
Zurück zum Zitat Balmain A, Gray J, Ponder B (2003) The genetics and genomics of cancer. Nat Genet 33:238–244CrossRefPubMed Balmain A, Gray J, Ponder B (2003) The genetics and genomics of cancer. Nat Genet 33:238–244CrossRefPubMed
6.
Zurück zum Zitat Helzlsouer KJ, Harris EL, Parshad R et al (1996) DNA repair proficiency: potential susceptibility factor for breast cancer. J Natl Cancer Inst 88(11):754–755CrossRefPubMed Helzlsouer KJ, Harris EL, Parshad R et al (1996) DNA repair proficiency: potential susceptibility factor for breast cancer. J Natl Cancer Inst 88(11):754–755CrossRefPubMed
7.
Zurück zum Zitat Lunn RM, Helzlsouer KJ, Parshad R et al (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21(4):551–555CrossRefPubMed Lunn RM, Helzlsouer KJ, Parshad R et al (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21(4):551–555CrossRefPubMed
8.
9.
Zurück zum Zitat Haiman CA, Hsu C, de Bakker PI et al (2008) Comprehensive association testing of common genetic variation in DNA repair pathway genes in relationship with breast cancer risk in multiple populations. Hum Mol Genet 17(6):825–834CrossRefPubMed Haiman CA, Hsu C, de Bakker PI et al (2008) Comprehensive association testing of common genetic variation in DNA repair pathway genes in relationship with breast cancer risk in multiple populations. Hum Mol Genet 17(6):825–834CrossRefPubMed
10.
Zurück zum Zitat Kuschel B, Auranen A, McBride S (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 11(12):1399–1407CrossRefPubMed Kuschel B, Auranen A, McBride S (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 11(12):1399–1407CrossRefPubMed
11.
Zurück zum Zitat Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11(12):1513–1530PubMed Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11(12):1513–1530PubMed
12.
Zurück zum Zitat Garcia-Closas M, Egan KM, Newcomb PA et al (2006) Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 119(4):376–388CrossRefPubMed Garcia-Closas M, Egan KM, Newcomb PA et al (2006) Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 119(4):376–388CrossRefPubMed
13.
Zurück zum Zitat Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11):1239–1241CrossRefPubMed Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11):1239–1241CrossRefPubMed
14.
Zurück zum Zitat Rahman N, Seal S, Thompson D (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167CrossRefPubMed Rahman N, Seal S, Thompson D (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167CrossRefPubMed
15.
16.
Zurück zum Zitat Wang Y, Cortez D, Yazdi P et al (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14:927–939PubMed Wang Y, Cortez D, Yazdi P et al (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14:927–939PubMed
17.
Zurück zum Zitat Greenberg RA, Sobhian B, Pathania S et al (2006) Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 20:34–46CrossRefPubMed Greenberg RA, Sobhian B, Pathania S et al (2006) Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 20:34–46CrossRefPubMed
18.
Zurück zum Zitat Scully R, Xie A, Nagaraju G (2004) Molecular functions of BRCA1 in the DNA damage response. Cancer Biol Ther 3:521–527PubMed Scully R, Xie A, Nagaraju G (2004) Molecular functions of BRCA1 in the DNA damage response. Cancer Biol Ther 3:521–527PubMed
19.
Zurück zum Zitat Liu Y, West SC (2002) Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res 4:9–13CrossRefPubMed Liu Y, West SC (2002) Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res 4:9–13CrossRefPubMed
20.
Zurück zum Zitat Xia B, Sheng Q, Nakanishi K et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719–729CrossRefPubMed Xia B, Sheng Q, Nakanishi K et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719–729CrossRefPubMed
21.
Zurück zum Zitat An G, Ng AY, Meka CS et al (2000) Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast, and bladder cancers. Cancer Res 60(24):7014–7020PubMed An G, Ng AY, Meka CS et al (2000) Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast, and bladder cancers. Cancer Res 60(24):7014–7020PubMed
22.
Zurück zum Zitat Hamaguchi M, Meth JL, von Klitzing C et al (2002) DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 99(21):13647–13652CrossRefPubMed Hamaguchi M, Meth JL, von Klitzing C et al (2002) DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 99(21):13647–13652CrossRefPubMed
23.
Zurück zum Zitat Rudd MF, Williams RD, Webb EL et al (2005) The predicted impact of coding single nucleotide polymorphisms database. Cancer Epidemiol Biomarkers Prev 14(11 Pt 1):2598–2604CrossRefPubMed Rudd MF, Williams RD, Webb EL et al (2005) The predicted impact of coding single nucleotide polymorphisms database. Cancer Epidemiol Biomarkers Prev 14(11 Pt 1):2598–2604CrossRefPubMed
24.
Zurück zum Zitat Savas S, Kim DY, Ahmad MF et al (2004) Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 13(5):801–807PubMed Savas S, Kim DY, Ahmad MF et al (2004) Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 13(5):801–807PubMed
25.
Zurück zum Zitat Nakken S, Alseth I, Rognes T (2007) Computational prediction of the effects of nonsynonymous single nucleotide polymorphisms in human DNA repair genes. Neuroscience 145(4):1273–1279CrossRefPubMed Nakken S, Alseth I, Rognes T (2007) Computational prediction of the effects of nonsynonymous single nucleotide polymorphisms in human DNA repair genes. Neuroscience 145(4):1273–1279CrossRefPubMed
26.
Zurück zum Zitat Beiner ME, Rosen B, Fyles A et al (2006) Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol Biomarkers Prev 15(9):1636–1640CrossRefPubMed Beiner ME, Rosen B, Fyles A et al (2006) Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol Biomarkers Prev 15(9):1636–1640CrossRefPubMed
27.
Zurück zum Zitat Sigurdson AJ, Hauptmann M, Chatterjee N et al (2004) Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer 4:9CrossRefPubMed Sigurdson AJ, Hauptmann M, Chatterjee N et al (2004) Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer 4:9CrossRefPubMed
28.
Zurück zum Zitat Kilpivaara O, Vahteristo P, Falck J et al (2004) CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 111(4):543–547CrossRefPubMed Kilpivaara O, Vahteristo P, Falck J et al (2004) CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 111(4):543–547CrossRefPubMed
29.
Zurück zum Zitat Barroso E, Milne RL, Fernandez LP et al (2006) FANCD2 associated with sporadic breast cancer risk. Carcinogenesis 27(9):1930–1937CrossRefPubMed Barroso E, Milne RL, Fernandez LP et al (2006) FANCD2 associated with sporadic breast cancer risk. Carcinogenesis 27(9):1930–1937CrossRefPubMed
30.
Zurück zum Zitat Landi S, Gemignani F, Canzian F et al (2006) DNA repair and cell cycle control genes and the risk of young-onset lung cancer. Cancer Res 66(22):11062–11069CrossRefPubMed Landi S, Gemignani F, Canzian F et al (2006) DNA repair and cell cycle control genes and the risk of young-onset lung cancer. Cancer Res 66(22):11062–11069CrossRefPubMed
31.
Zurück zum Zitat Poplawski T, Zadrozny M, Kolacinska A et al (2005) Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurrence and progression. Breast Cancer Res Treat 94(3):199–204CrossRefPubMed Poplawski T, Zadrozny M, Kolacinska A et al (2005) Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurrence and progression. Breast Cancer Res Treat 94(3):199–204CrossRefPubMed
32.
Zurück zum Zitat Lu J, Wei Q, Bondy ML et al (2006) Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women < or =55 years. Carcinogenesis 27(11):2209–2216CrossRefPubMed Lu J, Wei Q, Bondy ML et al (2006) Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women < or =55 years. Carcinogenesis 27(11):2209–2216CrossRefPubMed
33.
Zurück zum Zitat Allen-Brady K, Camp NJ (2005) Characterization of the linkage disequilibrium structure and identification of tagging-SNPs in five DNA repair genes. BMC Cancer 5:99CrossRefPubMed Allen-Brady K, Camp NJ (2005) Characterization of the linkage disequilibrium structure and identification of tagging-SNPs in five DNA repair genes. BMC Cancer 5:99CrossRefPubMed
34.
Zurück zum Zitat Sole X, Guino E, Valls J et al (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22(15):1928–1929CrossRefPubMed Sole X, Guino E, Valls J et al (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22(15):1928–1929CrossRefPubMed
35.
Zurück zum Zitat Loizidou MA, Michael T, Neuhausen SL et al (2009) DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus. Breast Cancer Res Treat 115(3):623–627CrossRefPubMed Loizidou MA, Michael T, Neuhausen SL et al (2009) DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus. Breast Cancer Res Treat 115(3):623–627CrossRefPubMed
36.
Zurück zum Zitat Pharoah PD, Antoniou A, Bobrow M et al (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33–36CrossRefPubMed Pharoah PD, Antoniou A, Bobrow M et al (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33–36CrossRefPubMed
37.
Zurück zum Zitat Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71CrossRefPubMed
38.
Zurück zum Zitat Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792CrossRefPubMed Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792CrossRefPubMed
39.
Zurück zum Zitat Hadjisavvas A, Charalambous E, Adamou A et al (2004) Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation. Cancer Genet Cytogenet 151(2):152–156CrossRefPubMed Hadjisavvas A, Charalambous E, Adamou A et al (2004) Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation. Cancer Genet Cytogenet 151(2):152–156CrossRefPubMed
40.
Zurück zum Zitat Loizidou M, Marcou Y, Anastasiadou V et al (2007) Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early onset breast cancer in Cyprus. Clin Genet 71(2):165–170CrossRefPubMed Loizidou M, Marcou Y, Anastasiadou V et al (2007) Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early onset breast cancer in Cyprus. Clin Genet 71(2):165–170CrossRefPubMed
41.
Zurück zum Zitat Loizidou MA, Michael T, Neuhausen SL et al (2008) Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus. Breast Cancer Res Treat 112(3):575–579CrossRefPubMed Loizidou MA, Michael T, Neuhausen SL et al (2008) Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus. Breast Cancer Res Treat 112(3):575–579CrossRefPubMed
42.
Zurück zum Zitat Pooley KA, Baynes C, Driver KE et al (2008) Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk. Cancer Epidemiol Biomarkers Prev 17(12):3482–3489CrossRefPubMed Pooley KA, Baynes C, Driver KE et al (2008) Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk. Cancer Epidemiol Biomarkers Prev 17(12):3482–3489CrossRefPubMed
43.
Zurück zum Zitat Han J, Haiman C, Niu T et al (2009) Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk. Breast Cancer Res Treat 115(3):613–622CrossRefPubMed Han J, Haiman C, Niu T et al (2009) Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk. Breast Cancer Res Treat 115(3):613–622CrossRefPubMed
44.
Zurück zum Zitat Kobayashi J, Antoccia A, Tauchi H et al (2004) NBS1 and its functional role in the DNA damage response. DNA Repair (Amst) 3(8–9):855–861CrossRef Kobayashi J, Antoccia A, Tauchi H et al (2004) NBS1 and its functional role in the DNA damage response. DNA Repair (Amst) 3(8–9):855–861CrossRef
45.
Zurück zum Zitat Jazayeri A, Jackson SP (2002) Screening the yeast genome for new DNA-repair genes. Genome Biol 3(4):reviews1009.1–reviews1009.5CrossRef Jazayeri A, Jackson SP (2002) Screening the yeast genome for new DNA-repair genes. Genome Biol 3(4):reviews1009.1–reviews1009.5CrossRef
46.
Zurück zum Zitat Merika M, Orkin SH (1993) DNA-binding specificity of GATA family transcription factors. Mol Cell Biol 13:3999–4010PubMed Merika M, Orkin SH (1993) DNA-binding specificity of GATA family transcription factors. Mol Cell Biol 13:3999–4010PubMed
47.
Zurück zum Zitat Lee PH, Shatkay H (2008) F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 36(Database issue):D820–D824PubMed Lee PH, Shatkay H (2008) F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 36(Database issue):D820–D824PubMed
48.
Zurück zum Zitat Osman F, Whitby MC (2007) Exploring the roles of Mus81-Eme1/Mms4 at perturbed replication forks. DNA Repair (Amst) 6(7):1004–1017CrossRef Osman F, Whitby MC (2007) Exploring the roles of Mus81-Eme1/Mms4 at perturbed replication forks. DNA Repair (Amst) 6(7):1004–1017CrossRef
49.
Zurück zum Zitat McPherson JP, Lemmers B, Chahwan R et al (2004) Involvement of mammalian Mus81 in genome integrity and tumor suppression. Science 304(5678):1822–1826CrossRefPubMed McPherson JP, Lemmers B, Chahwan R et al (2004) Involvement of mammalian Mus81 in genome integrity and tumor suppression. Science 304(5678):1822–1826CrossRefPubMed
50.
Zurück zum Zitat van den Bosch M, Bree RT, Lowndes NF (2003) The MRN complex: coordinating and mediating the response to broken chromosomes. EMBO Rep 4(9):844–849CrossRefPubMed van den Bosch M, Bree RT, Lowndes NF (2003) The MRN complex: coordinating and mediating the response to broken chromosomes. EMBO Rep 4(9):844–849CrossRefPubMed
51.
Zurück zum Zitat Liu Y, Ludes-Meyers J, Zhang Y et al (2002) Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 21(50):7680–7689CrossRefPubMed Liu Y, Ludes-Meyers J, Zhang Y et al (2002) Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 21(50):7680–7689CrossRefPubMed
52.
Zurück zum Zitat Gordon S, Akopyan G, Garban H et al (2006) Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25(8):1125–1142CrossRefPubMed Gordon S, Akopyan G, Garban H et al (2006) Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25(8):1125–1142CrossRefPubMed
53.
Zurück zum Zitat Gorlov IP, Gorlova OY, Sunyaev SR et al (2008) Shifting paradigm of association studies: value of rare single-nucleotide polymorphisms. Am J Hum Genet 82(1):100–112CrossRefPubMed Gorlov IP, Gorlova OY, Sunyaev SR et al (2008) Shifting paradigm of association studies: value of rare single-nucleotide polymorphisms. Am J Hum Genet 82(1):100–112CrossRefPubMed
Metadaten
Titel
Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population
verfasst von
Maria A. Loizidou
Marios A. Cariolou
Susan L. Neuhausen
Robert F. Newbold
Evy Bashiardes
Yiola Marcou
Thalia Michael
Maria Daniel
Eleni Kakouri
Panayiotis Papadopoulos
Simon Malas
Andreas Hadjisavvas
Kyriacos Kyriacou
Publikationsdatum
01.05.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0518-7

Weitere Artikel der Ausgabe 1/2010

Breast Cancer Research and Treatment 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.